Pharma Mar Sau Stock Current Valuation
| 0RC6 Stock | 75.72 2.97 4.08% |
Valuation analysis of Pharma Mar SAU helps investors to measure Pharma Mar's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Pharma Mar's Cash And Short Term Investments are comparatively stable compared to the past year. Begin Period Cash Flow is likely to gain to about 157.3 M in 2024, despite the fact that Change In Cash is likely to grow to (85.3 M). Fundamental drivers impacting Pharma Mar's valuation include:
Enterprise Value 1.2 B | Price Sales 98.1217 | Trailing PE 0.1469 |
Overvalued
Today
Please note that Pharma Mar's price fluctuation is very steady at this time. Calculation of the real value of Pharma Mar SAU is based on 3 months time horizon. Increasing Pharma Mar's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pharma stock is determined by what a typical buyer is willing to pay for full or partial control of Pharma Mar SAU. Since Pharma Mar is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharma Stock. However, Pharma Mar's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 75.72 | Real 68.27 | Hype 75.72 | Naive 75.77 |
The intrinsic value of Pharma Mar's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pharma Mar's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pharma Mar SAU helps investors to forecast how Pharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharma Mar more accurately as focusing exclusively on Pharma Mar's fundamentals will not take into account other important factors: Pharma Mar SAU Company Current Valuation Analysis
Pharma Mar's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pharma Mar Current Valuation | 1.23 B |
Most of Pharma Mar's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SAU is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pharma Mar SAU has a Current Valuation of 1.23 B. This is 83.04% lower than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The current valuation for all United Kingdom stocks is 92.57% higher than that of the company.
Pharma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in current valuation category among its peers.
Pharma Fundamentals
| Return On Equity | 0.0032 | ||||
| Return On Asset | -0.0065 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.23 B | ||||
| Shares Outstanding | 221.28 M | ||||
| Shares Owned By Insiders | 21.39 % | ||||
| Shares Owned By Institutions | 7.21 % | ||||
| Price To Sales | 98.12 X | ||||
| Revenue | 158.15 M | ||||
| Gross Profit | 182.7 M | ||||
| EBITDA | 4.55 M | ||||
| Net Income | 1.14 M | ||||
| Total Debt | 43.67 M | ||||
| Book Value Per Share | 10.39 X | ||||
| Cash Flow From Operations | (13.45 M) | ||||
| Earnings Per Share | 5.03 X | ||||
| Number Of Employees | 509 | ||||
| Beta | 0.044 | ||||
| Market Capitalization | 16.39 B | ||||
| Total Asset | 341.22 M | ||||
| Retained Earnings | 142.22 M | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 341.22 M | ||||
| Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SAU's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SAU based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.